Market Overview

UPDATE: Stifel Terminates Coverage on Corcept Therapeutics Due to Reallocation of Resources

Related CORT
Benzinga's Top Initiations
Warrant Exercises Generate $17.2M; Proceeds to Advance Next-Generation Compounds and Support Commercialization of Korlym

In a report published Monday, Stifel analyst Annabel Samimy terminated coverage on Corcept Therapeutics (NASDAQ: CORT).

In the report, Stifel noted, “Due to a reallocation of resources, we are discontinuing coverage of Corcept Therapeutics. Our last rating was Hold. Our last net loss estimates were ($0.53) for FY 2014, ($0.38) for 2015, breakeven for FY2016, $0.40 for FY2017, and $1.12 for FY 2018. However, these estimates should not be used as an indicator for the company going forward.”

Corcept Therapeutics closed on Friday at $4.08.

Latest Ratings for CORT

Apr 2015FBR CapitalInitiates Coverage onOutperform
Mar 2015Piper JaffrayUpgradesNeutralOverweight
Apr 2014Brinson PatrickInitiates Coverage onMarket Outperform

View More Analyst Ratings for CORT
View the Latest Analyst Ratings

Posted-In: Annabel Samimy StifelAnalyst Color Termination Analyst Ratings


Related Articles (CORT)

Around the Web, We're Loving...